Blog
RSS FeedPosted by Michael Wonder on 09 Sep 2022
Rare cancer sufferers fight to get drugs on PBS
9 September 2022 - People with rare cancers are being forced to sell their homes, raid their superannuation and fundraise ...
Posted by Michael Wonder on 09 Sep 2022
PBAC Public Summary Documents (first time rejections and deferrals) - May 2022 meeting
9 September 2022 - The Public Summary Documents (first time rejections and deferrals) from the May 2022 PBAC meeting are now ...
Posted by Michael Wonder on 08 Sep 2022
Large scale population based surveys linked to administrative health databases as a source of data on health utilities in Australia
8 September 2022 - It is ideal that modelling studies apply health utility values that are compatible, derived using common methods, ...
Posted by Michael Wonder on 07 Sep 2022
Cheaper scripts for millions
7 September 2022 - For the first time in its 75 year history, the maximum cost of general scripts under ...
Posted by Michael Wonder on 05 Sep 2022
Review of Efficient Funding of Chemotherapy Program - interim report
5 September 2022 - The Efficient Funding of Chemotherapy review seeks to investigate current processes involved in the production, distribution ...
Posted by Michael Wonder on 05 Sep 2022
Collaboration arrangement between the Department of Health and Aged Care and Health Technology Assessment bodies in the United Kingdom and Canada
5 September 2022 - The Department of Health and Aged Care has signed an international collaboration arrangement with five like minded ...
Posted by Michael Wonder on 04 Sep 2022
Australia among world's best in treating debilitating and often fatal muscle disorder
4 September - Australia has become one of the first countries in the world to fund a new, next-generation treatment ...
Posted by Michael Wonder on 02 Sep 2022
Updated agenda for the November 2022 PBAC meeting
2 September 2022 - The agenda for the November 2022 PBAC meeting has been updated. ...
Posted by Michael Wonder on 01 Sep 2022
Critical kidney disease medication listed on the PBS
1 September 2022 - A life changing treatment for chronic kidney disease will be made available to thousands of Australians through ...
Posted by Michael Wonder on 01 Sep 2022
Antengene announces Xpovia included for reimbursement by the PBS in Australia for the treatment of patients with relapsed and/or refractory multiple myeloma
1 September 2022 - Xpovio (selinexor) is the first and only selective inhibitor of nuclear export (SINE) inhibitor approved by the ...
Posted by Michael Wonder on 01 Sep 2022
PBS listing for ovarian cancer and kidney disease
1 September 2022 - From 1 September 2022, Australians will have access to new and expanded medicines on the Pharmaceutical Benefits ...
Posted by Michael Wonder on 31 Aug 2022
Kidney disease drug dapagliflozin added to Pharmaceutical Benefits Scheme
31 August 2022 - Lachlan Ross describes his more than a decade-long battle with kidney failure as "very long, and very ...
Posted by Michael Wonder on 31 Aug 2022
Schedule of Pharmaceutical Benefits - 1 September 2022
1 September 2022 - The September 2022 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 31 Aug 2022
Pharmaceutical Benefits Scheme supplied medications
30 August 2022 - Key findings about health and population characteristics from the National Health Survey (NHS) and the Pharmaceutical Benefits ...
Posted by Michael Wonder on 30 Aug 2022
Spinal muscular atrophy community rejoices as 'life-changing' drug Spinraza approved for adults
30 August 2022 - "I have hope again," says Juanita Vernon as the 52 year old tearfully discusses her feelings about ...